Rinvoq

Oman · access guide

How to access Rinvoq from Oman, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Oman patient with moderate-to-severe atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, or axial spondyloarthritis may receive a prescription for Rinvoq (upadacitinib) from their treating dermatologist, rheumatologist, or gastroenterologist. Rinvoq is FDA-approved in the United States and manufactured by AbbVie. It is an oral once-daily selective JAK1 inhibitor that has extended across multiple immune-mediated conditions. Access through Oman hospital pharmacies varies by indication; when your indication is not on a formulary, or when the specific strength is not locally stocked, a named-patient import route remains legitimate.

This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.

The clinical situation

Rinvoq is an oral JAK1-selective inhibitor taken once daily. Dosing differs by indication, 15 mg is common for rheumatoid and psoriatic arthritis, higher strengths for inflammatory bowel disease induction. Eligibility considers prior therapy history, cardiovascular and malignancy risk screening in line with the FDA boxed warning (and updated EU labeling) applicable to the JAK class, and ongoing monitoring. Your physician will confirm baseline labs, TB screening, and vaccination status per FDA labeling.

Is Rinvoq legally importable into Oman?

Yes, through the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) named-patient / personal-use import framework. The pathway allows a Oman-licensed physician to import a medicine not locally registered for the specific indication when: (a) the medicine is approved by a recognised reference authority such as the US FDA or EMA, (b) no clinically equivalent locally available alternative is suitable for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.

Rinvoq is locally registered in Oman for several indications, so many patients access it through hospital pharmacies. The named-patient pathway is relevant when the indication is outside the local label, when the specific strength is out of stock, or when institutional procurement timing is not clinically workable.

How the pathway works, step by step

1. **Consultation with your treating physician.** Clinical decision with documented severity and prior therapy history.
2. **Confirming the import rationale.** Indication, strength, or supply-gap rationale is documented.
3. **DGPADC named-patient application.** The physician or hospital files the application with clinical rationale, patient reference, product details, and chain-of-custody plan.
4. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from authorised distribution.
5. **Shipment.** Rinvoq is an oral tablet with standard storage; shipment includes tamper-evident packaging and chain-of-custody documentation.
6. **Arrival and first dose.** The dispensing facility or pharmacy releases product against the physician's prescription.

What documentation your physician needs

Your physician will typically need to provide:

- Clinical rationale letter confirming diagnosis, severity, prior therapies, and Rinvoq as the indicated treatment
- Verification of their Oman medical licence
- Patient identifier
- Pre-treatment screening confirmation (TB, lipids, infection screening per labeling)
- Planned dosing regimen and follow-up cadence

Reserve Meds provides a physician documentation kit that bundles the templates DGPADC reviewers expect to see for JAK-class therapies, including the cardiovascular/malignancy-risk discussion expected for this class.

Costs and timing

Rinvoq's US cash-pay drug-only reference price for a 30-tablet month supply at 15 mg sits in a broad indicative range of roughly USD 6,500-7,500. Higher strengths cost more. International logistics, DGPADC documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. Indicative range.

Indicative timing for first dose after cohort intake opens is 10-21 days from the moment a complete application is submitted. Refills ship on a rolling basis.

Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Rinvoq specifically, we provide:

- **Sourcing.** Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- **Documentation.** Regulatory package for your physician and for DGPADC review.
- **Logistics.** Tamper-evident, internationally tracked shipment.
- **Concierge case lead.** A named point of contact.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician.

Frequently asked

Is this legal in Oman? Yes, when executed through the DGPADC named-patient / personal-use framework with appropriate documentation.

What about the JAK class warnings? The FDA boxed warning on JAK inhibitors (CV events, malignancy, thrombosis, serious infection) applies across the class. Your physician assesses risk-benefit and monitors per labeling.

Can a locally registered JAK work instead? Your physician will consider any locally registered alternative that fits your case. If the clinical rationale for Rinvoq specifically is documented, the named-patient pathway supports the gap.

Will private insurance cover this? Cash-pay is the default. Some insurers reimburse named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.
Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.
reservemeds.com · hello@reservemeds.com